RxDoctor Payments Data

Christopher Berchelmann, MD

Internal Medicine · Plant City, FLNPI 1780757963

Payments from drug & device makers

$11,772in general payments, 2019–2025

Across 698 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Boehringer Ingelheim$788
  • Pfizer$514
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$11,725100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,772 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$178,492
Medicare patients
329
Services billed
2,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$185,034
EliquisApixaban88$128,365
OzempicSemaglutide79$83,077
MounjaroTirzepatide57$66,647
JanuviaSitagliptin Phosphate67$53,511
RybelsusSemaglutide22$47,030
Repatha SureclickEvolocumab35$36,224
FarxigaDapagliflozin Propanediol20$33,713
Tresiba Flextouch U-200Insulin Degludec12$30,108
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$23,748
MyrbetriqMirabegron30$21,779
EntrestoSacubitril/Valsartan16$18,238
GemtesaVibegron13$16,059
TrulicityDulaglutide11$14,385
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$12,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$788$185,034169 claims
Novo NordiskOzempic, Rybelsus$2,122$130,106101 claims
PfizerEliquis$514$128,36588 claims
Lilly USA, LLCMounjaro, Trulicity$1,316$81,03268 claims
MerckJanuvia$164$53,51167 claims
AstraZenecaFarxiga, Brilinta$1,415$39,12832 claims
Astellas Pharma US IncMyrbetriq$79$21,77930 claims
NovartisEntresto$111$18,23816 claims
Sumitomo Pharma America, Inc.Gemtesa$95$16,05913 claims
AbbVieLinzess, Synthroid$1,069$12,76955 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$207$8,71714 claims
Arbor Pharmaceuticals, Inc.Edarbi$108$5,99516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Plant City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →